{"id":10750,"date":"2021-09-07T09:06:05","date_gmt":"2021-09-07T09:06:05","guid":{"rendered":"https:\/\/i3tk.org\/demo2\/?p=10750"},"modified":"2021-09-07T09:06:08","modified_gmt":"2021-09-07T09:06:08","slug":"heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients","status":"publish","type":"post","link":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/","title":{"rendered":"Hetero\u2019s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patients"},"content":{"rendered":"\n<p>HYDERABAD: Hyderabad-based pharma player Hetero has received emergency use authorisation (EUA) from the\u00a0<a class=\"\" href=\"https:\/\/timesofindia.indiatimes.com\/topic\/Drugs-Controller\">Drugs Controller<\/a>\u00a0General of India (DCGI) for restricted use of its generic version of Tocilizumab in India.<\/p>\n\n\n\n<p>Hetero\u2019s Tocilizumab biosimilar, which has been named\u00a0<a class=\"\" href=\"https:\/\/timesofindia.indiatimes.com\/topic\/Tocira\">Tocira<\/a>, has been granted the nod for adult Covid-19 patients that have been hospitalized and are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (<a class=\"\" href=\"https:\/\/timesofindia.indiatimes.com\/topic\/ECMO\">ECMO<\/a>).<\/p>\n\n\n\n<p>Hetero\u2019s Tocira 400mg\/20ml, which is a biosimilar version of\u00a0<a class=\"\" href=\"https:\/\/timesofindia.indiatimes.com\/topic\/Roche\">Roche<\/a>\u2019s Actemra and\u00a0<a class=\"\" href=\"https:\/\/timesofindia.indiatimes.com\/topic\/RoActemra\">RoActemra<\/a>, will be rolled out from September end, Hetero Group said on Monday.<\/p>\n\n\n\n<p>The drug will be manufactured by Hetero\u2019s biologics arm Hetero Biopharma at its dedicated biologics facility based at Jadcherla in Hyderabad. Tocira will be marketed by Hetero\u2019s associate company Hetero Healthcare in India.<\/p>\n\n\n\n<p>Commenting on the development, Hetero Group chairman B Partha Saradhi Reddy said the EUA nod to Tocira demonstrates Hetero\u2019s technical capabilities and commitment to bringing important therapeutics relevant to Covid care.<\/p>\n\n\n\n<p>\u201cThis approval is extremely crucial for supply security in India considering a global shortage of Tocilizumab. We will be working closely with the government to ensure equitable distribution,\u201d Reddy said.<br>Share to Twitter<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HYDERABAD: Hyderabad-based pharma player Hetero has received emergency use authorisation [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10399,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[87],"tags":[],"class_list":["post-10750","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-resources"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v18.8 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hetero\u2019s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patients - International Institute of Innovation and Technology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hetero\u2019s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patients\" \/>\n<meta property=\"og:description\" content=\"HYDERABAD: Hyderabad-based pharma player Hetero has received emergency use authorisation [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"International Institute of Innovation and Technology\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/International-Institute-of-Innovation-and-Technology-101979535699954\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-07T09:06:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-07T09:06:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i3tk.org\/demo2\/wp-content\/uploads\/2021\/07\/steven-cornfield-jWPNYZdGz78-unsplash.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"427\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@i3tkolkata\" \/>\n<meta name=\"twitter:site\" content=\"@i3tkolkata\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/#\\\/schema\\\/person\\\/2ed104da3b2d63ba12c40da792d0bf2e\"},\"headline\":\"Hetero\u2019s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patients\",\"datePublished\":\"2021-09-07T09:06:05+00:00\",\"dateModified\":\"2021-09-07T09:06:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/\"},\"wordCount\":210,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/wp-content\\\/uploads\\\/2021\\\/07\\\/steven-cornfield-jWPNYZdGz78-unsplash.jpg\",\"articleSection\":[\"Resources\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/\",\"url\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/\",\"name\":\"Hetero\u2019s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patients - International Institute of Innovation and Technology\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/wp-content\\\/uploads\\\/2021\\\/07\\\/steven-cornfield-jWPNYZdGz78-unsplash.jpg\",\"datePublished\":\"2021-09-07T09:06:05+00:00\",\"dateModified\":\"2021-09-07T09:06:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/wp-content\\\/uploads\\\/2021\\\/07\\\/steven-cornfield-jWPNYZdGz78-unsplash.jpg\",\"contentUrl\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/wp-content\\\/uploads\\\/2021\\\/07\\\/steven-cornfield-jWPNYZdGz78-unsplash.jpg\",\"width\":640,\"height\":427},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/world-news\\\/resources\\\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hetero\u2019s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/#website\",\"url\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/\",\"name\":\"International Institute of Innovation and Technology\",\"description\":\"Advancing New Frontiers in Research &amp; Education\",\"publisher\":{\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/#organization\",\"name\":\"International Institute of Innovation and Technology (I3TK)\",\"url\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/i3tk-logo-v1.jpg\",\"contentUrl\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/i3tk-logo-v1.jpg\",\"width\":200,\"height\":200,\"caption\":\"International Institute of Innovation and Technology (I3TK)\"},\"image\":{\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/International-Institute-of-Innovation-and-Technology-101979535699954\",\"https:\\\/\\\/x.com\\\/i3tkolkata\",\"https:\\\/\\\/www.instagram.com\\\/i3tkolkata\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCOXcio6zwQO3YSQkwoZKNrQ\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/#\\\/schema\\\/person\\\/2ed104da3b2d63ba12c40da792d0bf2e\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/52146bcbad3565e9d842646770b21e26751c22d5978bb87fce2c8fd80777bbda?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/52146bcbad3565e9d842646770b21e26751c22d5978bb87fce2c8fd80777bbda?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/52146bcbad3565e9d842646770b21e26751c22d5978bb87fce2c8fd80777bbda?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/i3tk.org\\\/demo2\"],\"url\":\"https:\\\/\\\/i3tk.org\\\/demo2\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hetero\u2019s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patients - International Institute of Innovation and Technology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/","og_locale":"en_US","og_type":"article","og_title":"Hetero\u2019s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patients","og_description":"HYDERABAD: Hyderabad-based pharma player Hetero has received emergency use authorisation [&hellip;]","og_url":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/","og_site_name":"International Institute of Innovation and Technology","article_publisher":"https:\/\/www.facebook.com\/International-Institute-of-Innovation-and-Technology-101979535699954","article_published_time":"2021-09-07T09:06:05+00:00","article_modified_time":"2021-09-07T09:06:08+00:00","og_image":[{"width":640,"height":427,"url":"https:\/\/i3tk.org\/demo2\/wp-content\/uploads\/2021\/07\/steven-cornfield-jWPNYZdGz78-unsplash.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@i3tkolkata","twitter_site":"@i3tkolkata","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/#article","isPartOf":{"@id":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/"},"author":{"name":"admin","@id":"https:\/\/i3tk.org\/demo2\/#\/schema\/person\/2ed104da3b2d63ba12c40da792d0bf2e"},"headline":"Hetero\u2019s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patients","datePublished":"2021-09-07T09:06:05+00:00","dateModified":"2021-09-07T09:06:08+00:00","mainEntityOfPage":{"@id":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/"},"wordCount":210,"commentCount":0,"publisher":{"@id":"https:\/\/i3tk.org\/demo2\/#organization"},"image":{"@id":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/i3tk.org\/demo2\/wp-content\/uploads\/2021\/07\/steven-cornfield-jWPNYZdGz78-unsplash.jpg","articleSection":["Resources"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/","url":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/","name":"Hetero\u2019s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patients - International Institute of Innovation and Technology","isPartOf":{"@id":"https:\/\/i3tk.org\/demo2\/#website"},"primaryImageOfPage":{"@id":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/#primaryimage"},"image":{"@id":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/i3tk.org\/demo2\/wp-content\/uploads\/2021\/07\/steven-cornfield-jWPNYZdGz78-unsplash.jpg","datePublished":"2021-09-07T09:06:05+00:00","dateModified":"2021-09-07T09:06:08+00:00","breadcrumb":{"@id":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/#primaryimage","url":"https:\/\/i3tk.org\/demo2\/wp-content\/uploads\/2021\/07\/steven-cornfield-jWPNYZdGz78-unsplash.jpg","contentUrl":"https:\/\/i3tk.org\/demo2\/wp-content\/uploads\/2021\/07\/steven-cornfield-jWPNYZdGz78-unsplash.jpg","width":640,"height":427},{"@type":"BreadcrumbList","@id":"https:\/\/i3tk.org\/demo2\/world-news\/resources\/heteros-tocilizumab-biosimilar-gets-dcgi-nod-for-hospitalised-covid-19-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/i3tk.org\/demo2\/"},{"@type":"ListItem","position":2,"name":"Hetero\u2019s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patients"}]},{"@type":"WebSite","@id":"https:\/\/i3tk.org\/demo2\/#website","url":"https:\/\/i3tk.org\/demo2\/","name":"International Institute of Innovation and Technology","description":"Advancing New Frontiers in Research &amp; Education","publisher":{"@id":"https:\/\/i3tk.org\/demo2\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/i3tk.org\/demo2\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/i3tk.org\/demo2\/#organization","name":"International Institute of Innovation and Technology (I3TK)","url":"https:\/\/i3tk.org\/demo2\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/i3tk.org\/demo2\/#\/schema\/logo\/image\/","url":"https:\/\/i3tk.org\/demo2\/wp-content\/uploads\/2022\/01\/i3tk-logo-v1.jpg","contentUrl":"https:\/\/i3tk.org\/demo2\/wp-content\/uploads\/2022\/01\/i3tk-logo-v1.jpg","width":200,"height":200,"caption":"International Institute of Innovation and Technology (I3TK)"},"image":{"@id":"https:\/\/i3tk.org\/demo2\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/International-Institute-of-Innovation-and-Technology-101979535699954","https:\/\/x.com\/i3tkolkata","https:\/\/www.instagram.com\/i3tkolkata\/","https:\/\/www.youtube.com\/channel\/UCOXcio6zwQO3YSQkwoZKNrQ"]},{"@type":"Person","@id":"https:\/\/i3tk.org\/demo2\/#\/schema\/person\/2ed104da3b2d63ba12c40da792d0bf2e","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/52146bcbad3565e9d842646770b21e26751c22d5978bb87fce2c8fd80777bbda?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/52146bcbad3565e9d842646770b21e26751c22d5978bb87fce2c8fd80777bbda?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/52146bcbad3565e9d842646770b21e26751c22d5978bb87fce2c8fd80777bbda?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/i3tk.org\/demo2"],"url":"https:\/\/i3tk.org\/demo2\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/i3tk.org\/demo2\/wp-json\/wp\/v2\/posts\/10750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i3tk.org\/demo2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i3tk.org\/demo2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i3tk.org\/demo2\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/i3tk.org\/demo2\/wp-json\/wp\/v2\/comments?post=10750"}],"version-history":[{"count":0,"href":"https:\/\/i3tk.org\/demo2\/wp-json\/wp\/v2\/posts\/10750\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/i3tk.org\/demo2\/wp-json\/wp\/v2\/media\/10399"}],"wp:attachment":[{"href":"https:\/\/i3tk.org\/demo2\/wp-json\/wp\/v2\/media?parent=10750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i3tk.org\/demo2\/wp-json\/wp\/v2\/categories?post=10750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i3tk.org\/demo2\/wp-json\/wp\/v2\/tags?post=10750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}